Firm to double headcount
Biogelx expands after university licensing deal
Healthcare firm Biogelx is expanding at BioCity Scotland and doubling headcount after signing a licensing deal with Strathclyde university.
This international, exclusive deal will allow the company to expand into regenerative medicine, cell-based therapy and drug delivery applications, with annual market value of over $3 billion.
Its research is aimed at tackling a wide range of health conditions, including nerve, bone and cartilage repair.
Earlier this year, the company established a US subsidiary, Biogelx Inc. in New York. This new base has allowed the company to further expand into the highly lucrative North American market – currently the biggest suppliers of regenerative medicine therapies.
Dr. David Lightbody (pictured), chief executive, said: “It’s been a thrilling year for Bioglex and securing this first of a kind technology is a game changer for us. We now have a fantastic platform to extend our activities from laboratory-based into direct clinical applications and export our technology into worldwide markets.”
Dr Diane Harbison, managing director of BioCity Scotland said: “We are delighted to support the continued growth and success of one of our first tenants. BioCity Scotland is the perfect incubator for life sciences companies to flourish and Biogelx is the perfect example of what can be achieved in this environment.”